Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label
Sarepta Therapeutics, Inc. today announced the submission of an efficacy supplement to the Biologics License Application (BLA) for ELEVIDYS to expand its labeled indication. The company also shared that it completed the Phase 3 EMBARK…Learn More